BERLIN, Feb. 27 (Xinhua) -- The German medical technology company Fresenius on Tuesday threatened to reverse its takeover of U.S. pharmaceutical producer Akorn worth 4.4 billion euros (5.38 billion U.S. dollars).
Fresenius CEO Stephan Sturm told media his firm had received anonymously-submitted information about irregularities in Akorn's product development. The firm stands accused of having breached regulations by the Food and Drug Administration (FDA) in releasing medication on the U.S. market.
Sturm said the issues were unknown by Fresenius prior to the merge despite having conducted the "most comprehensive and careful" evaluation of his career.
However, Sturm noted that it was still too early to speculate about the outcome of an independent investigation which is currently underway.
Fresenius, which is listed on the Frankfurt-based DAX stock exchange, has recently published record profit (1.8 billion euros) and revenue (33.9 billion euros) figures for the 14th consecutive year.
The Bad Homburg-based company hereby also benefited from a one-off effect of 1.28 billion euros on its profits created by the recent U.S. corporate tax reform.
